Comparative Pharmacology
Head-to-head clinical analysis: AMINOSYN PF 10 versus TRAVASOL 2 75 SULFITE FREE W ELECTROLYTES IN DEXTROSE 20 IN PLASTIC CONTAINER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AMINOSYN PF 10 versus TRAVASOL 2 75 SULFITE FREE W ELECTROLYTES IN DEXTROSE 20 IN PLASTIC CONTAINER.
AMINOSYN-PF 10% vs TRAVASOL 2.75% SULFITE FREE W/ ELECTROLYTES IN DEXTROSE 20% IN PLASTIC CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Aminosyn-PF 10% is a crystalline amino acid solution that provides essential and non-essential amino acids for protein synthesis and nitrogen balance in neonates and pediatric patients.
Travasol 2.75% with electrolytes in dextrose 20% provides amino acids for protein synthesis, dextrose as a caloric source, and electrolytes for maintenance of fluid and electrolyte balance. Dextrose stimulates insulin release, promoting cellular uptake of glucose and amino acids, while electrolytes help maintain osmolality and acid-base balance.
Intravenous infusion: 1-1.5 g amino acids/kg/day (protein equivalent) as part of total parenteral nutrition. Typical rate: 0.5-2.0 mL/kg/hour initially, titrated to metabolic needs.
Intravenous infusion: Typical adult dose is 1-2 L/day of TRAVASOL 2.75% with 20% dextrose, administered as continuous infusion via central line. Rate should be adjusted based on metabolic and fluid needs.
None Documented
None Documented
Variable; amino acids have half-lives of minutes to hours; clinical context: continuous infusion maintains steady state
Not applicable; TRAVASOL is a mixture of dextrose, electrolytes, and amino acids with no defined terminal elimination half-life as individual components are metabolized or excreted rapidly.
Renal: >90% as amino acids and metabolites; <10% fecal/biliary
Renal: 100% as free water, electrolytes, and dextrose metabolites; no biliary or fecal elimination.
Category C
Category C
Parenteral Nutrition Solution
Parenteral Nutrition Solution